The British Journal of Psychiatry · 2011 · 108 citations · 25 references
MedicineNeurosciencePsychiatryNeurochemistryNeuropsychiatryNeuropsychologyGlutamatergic NeurochemistryMental HealthMental IllnessNeuropsychological AssessmentSchizophrenia Spectrum DisordersFirst-episode SchizophreniaGlutamatergic DysfunctionGlutamatergic NeurotransmissionGlutamine MetabolismGrey Matter PathologyNeuroimaging MarkersSocial Functioning AssessmentSocial Functioning Impairment
BACKGROUND: Thalamic glutamine loss and grey matter reduction suggest neurodegeneration in first-episode schizophrenia, but the duration is unknown. AIMS: To observe glutamine and glutamate levels, grey matter volumes and social functioning in patients with schizophrenia followed to 80 months after diagnosis. METHOD: Grey matter volumes and proton magnetic resonance spectroscopy metabolites in left anterior cingulate and left thalamus were measured in 17 patients with schizophrenia before medication and 10 and 80 months after diagnosis. Social functioning was assessed with the Life Skills Profile Rating Scale (LSPRS) at 80 months. RESULTS: The sum of thalamic glutamate and glutamine levels decreased over 80 months, and correlated inversely with the LSPRS. Thalamic glutamine and grey matter loss were significantly correlated in frontal, parietal, temporal and limbic regions. CONCLUSIONS: Brain metabolite loss is correlated with deteriorated social functioning and grey matter losses in schizophrenia, consistent with neurodegeneration.
25
Scale for the Assessment of Negative Symptoms (SANS)*
The British Journal of Psychiatry · 1989 · 2.7K citations
Medicine, Psychiatry, Psychology +17
Glutamate Receptor Dysfunction and Schizophrenia
John W. Olney · Archives of General Psychiatry · 1995 · 1.7K citations
Medicine, Neuroscience, Psychiatry +17